Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index; 11 of the 38 sources its claims cite were checked for support.

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas

Open access

Published version of a preprint

Abstract

PURPOSE: p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53 wild-type and MDM2-amplified cancers. However, this biomarker hypothesis has not been tested in patients or patient-derived models for GBM. EXPERIMENTAL DESIGN: We performed a preclinical evaluation of RG7112 MDM2 inhibitor, across a panel of 36 patient-derived GBM cell lines (PDCL), each genetically characterized according to their P53 pathway status. We then performed a pharmacokinetic (PK) profiling of RG7112 distribution in mice and evaluated the therapeutic activity of RG7112 in orthotopic and subcutaneous GBM models. RESULTS: MDM2-amplified PDCLs were 44 times more sensitive than TP53-mutated lines that showed complete resistance at therapeutically attainable concentrations (avg. IC50 of 0.52 μmol/L vs. 21.9 μmol/L). MDM4-amplified PDCLs were highly sensitive but showed intermediate response (avg. IC50 of 1.2 μmol/L), whereas response was heterogeneous in TP53 wild-type PDCLs with normal MDM2/4 levels (avg. IC50 of 7.7 μmol/L). In MDM2-amplified lines, RG7112 restored p53 activity inducing robust p21 expression and apoptosis. PK profiling of RG7112-treated PDCL intracranial xenografts demonstrated that the compound significantly crosses the blood-brain and the blood-tumor barriers. Most importantly, treatment of MDM2-amplified/TP53 wild-type PDCL-derived model (subcutaneous and orthotopic) reduced tumor growth, was cytotoxic, and significantly increased survival. CONCLUSIONS: These data strongly support development of MDM2 inhibitors for clinical testing in MDM2-amplified GBM patients. Moreover, significant efficacy in a subset of non-MDM2-amplified models suggests that additional markers of response to MDM2 inhibitors must be identified.

Overview

CoChat Summary

TL;DR

RG7112, an MDM2 inhibitor, was tested across 36 patient-derived glioblastoma cell lines and mouse models; MDM2-amplified/TP53 wild-type lines were most sensitive, and orthotopic treatment increased survival. The data support clinical testing in MDM2-amplified GBM while indicating that additional response markers are needed.

Key findings

  • MDM2-amplified PDCLs were 44 times more sensitive than TP53-mutated lines at therapeutically attainable concentrations (average IC50 0.52 μM vs 21.9 μM); MDM4-amplified PDCLs had intermediate sensitivity (average IC50 1.2 μM), and TP53 wild-type PDCLs with normal MDM2/4 levels were heterogeneous (average IC50 7.7 μM).
  • In MDM2-amplified lines, RG7112 restored p53 activity, induced p21 expression and apoptosis; PK profiling in intracranial xenografts showed tumor-hemisphere Cmax of 3328 ng/g (4.8 μM) and contralateral-hemisphere Cmax of 2025 ng/g (2.9 μM), both above the 0.5 μM in vitro IC50, with brain-to-plasma AUC ratio 0.198 in tumor vs 0.106 in contralateral brain (1.9-fold greater).
  • In vivo, subcutaneous 3731 MDM2-amplified tumors showed complete growth suppression and 80% regression during 21 days of treatment (p=0.003), with rapid regrowth after withdrawal; orthotopic tumor volume decreased from 4.91 mm3 to 4.28 mm3 (13% decrease) vs vehicle increase from 5.97 to 84.84 mm3 (14.2-fold), and RG7112 prolonged survival (p=0.0003), with a 50% increase in median survival.
  • MDM2 amplification did not affect prognosis: 43/696 (6.2%) newly diagnosed GBM were MDM2-amplified, with median overall survival 15.5 months in both amplified and non-amplified groups; MDM2 amplification and TP53 status were maintained at recurrence.

Methods

  • Preclinical evaluation across 36 GBM cell lines, including 32 patient-derived cell lines from two cohorts plus 4 commercial lines, genetically characterized for TP53, MDM2 and MDM4 status; RG7112 sensitivity was measured by 72-hour proliferation assays with IC50 determination.
  • In vivo studies used orthotopic (luciferase-labeled, intracranial) and subcutaneous GBM xenografts in nude mice; RG7112 was given by oral gavage at 100 mg/kg once daily, 5 days/week for 3 weeks, with bioluminescence, MRI, survival, and pharmacodynamic analyses.
  • Pharmacokinetics measured RG7112 in plasma, brain hemispheres and subcutaneous tumors by LC-MS/MS; statistical analyses included ANOVA/Tukey, t-tests, Kaplan-Meier/log-rank tests, and non-compartmental PK analysis with the Bailer method for destructive sampling.

Limitations

  • Stated: destructive PK sampling meant variability for parameters other than AUC0-t could not be determined and no statistical tests were performed on those parameters; intravascular drug/blood contribution to brain AUCs could not be excluded because GBM vasculature includes poorly perfused vessels; orthotopic tumor marker changes after 3 weeks were not statistically significant; resistance mechanisms remain unclear, and TP53 sequencing of recurrent tumors did not detect mutations; MDM4 findings require confirmation in additional cell lines; additional predictive markers are needed.
  • Evident: only 2/32 PDCLs had MDM2 high-level amplification, limiting generalizability; efficacy was greater in subcutaneous than orthotopic models, likely due to higher drug exposure; all efficacy data are preclinical, with no clinical trial results reported here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1015

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 2 Not valid · 18 Not checked · 115 Own results and interpretations

92 more claims · 1 with their cited sources checked

Create a free account to see all 144 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 48 references

Cited by

See all 114

Metadata

Authors
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., Ligon, A. H., Mokhtari, K., Hoang-Xuan, K., Sanson, M., Alexander, B. M., Wen, P. Y., Delattre, J.-Y., Ligon, K. L., & Idbaih, A.
Affiliations
  • 1Inserm, U 1127, Paris, France.
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Saint-Louis (FR)
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • Center for Neuro-Oncology (US)
Corresponding author
Ligon, Keith L.
Venue
Clinical Cancer Research
Published
2016-02-29
Volume
22
Issue
5
Pages
1185-1196
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1941304965
Cited by
114
References
48
Citations by year
2026: 2 · 2025: 11 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 8 · 2020: 14 · 2019: 11 · 2018: 10 · 2017: 7 · 2016: 8
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P01CA142536, R01CA170592, R01CA188228, P50CA165962)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
RG7112, MDM2 inhibitors, glioblastoma, MDM2 amplification, wild-type p53, p53 pathway, pharmacokinetics, blood-brain barrier penetration, orthotopic xenograft, subcutaneous xenograft, p21 expression, apoptosis, predictive biomarkers
MeSH terms
Animals, Glioblastoma, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Imidazolines, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1015
The paper
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., Ligon, A. H., Mokhtari, K., Hoang-Xuan, K., Sanson, M., Alexander, B. M., Wen, P. Y., Delattre, J.-Y., Ligon, K. L., & Idbaih, A. (2016). Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.